Danielle Antalffy
Stock Analyst at UBS
(3.48)
# 926
Out of 5,150 analysts
202
Total ratings
46.55%
Success rate
5.63%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Neutral | $8 → $9 | $7.93 | +13.49% | 5 | Feb 26, 2026 | |
| SYK Stryker | Maintains: Neutral | $386 → $400 | $381.89 | +4.74% | 7 | Feb 24, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $23.41 | -6.02% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $30.99 | +77.48% | 14 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $140 → $120 | $72.21 | +66.18% | 15 | Feb 5, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $95.75 | -10.18% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $85.22 | +11.48% | 14 | Jan 12, 2026 | |
| SGHT Sight Sciences | Maintains: Buy | $7 → $12 | $5.41 | +121.81% | 3 | Dec 23, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $64.32 | +41.48% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $115.37 | +25.68% | 3 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $26.56 | +133.43% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $102 | $95.60 | +6.69% | 12 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $242.89 | +64.68% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $1.47 | +297.96% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $13.56 | +17.99% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $72.90 | +30.32% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $19.03 | +10.35% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $501.18 | +19.72% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $245.30 | -12.76% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $25.79 | +121.02% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $113.10 | +30.86% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $4.03 | -44.17% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $3.53 | +23,271.10% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $29.22 | -52.09% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $77.84 | +28.47% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $13.95 | -13.98% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $34.96 | +28.72% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $171.49 | +60.36% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.87 | +596.86% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.31 | +565.61% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $6.87 | +773.36% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.79 | +1,798.73% | 1 | Sep 1, 2020 |
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $8 → $9
Current: $7.93
Upside: +13.49%
Stryker
Feb 24, 2026
Maintains: Neutral
Price Target: $386 → $400
Current: $381.89
Upside: +4.74%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $23.41
Upside: -6.02%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $30.99
Upside: +77.48%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $140 → $120
Current: $72.21
Upside: +66.18%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $95.75
Upside: -10.18%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $85.22
Upside: +11.48%
Sight Sciences
Dec 23, 2025
Maintains: Buy
Price Target: $7 → $12
Current: $5.41
Upside: +121.81%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $64.32
Upside: +41.48%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $115.37
Upside: +25.68%
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $26.56
Upside: +133.43%
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $95.60
Upside: +6.69%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $242.89
Upside: +64.68%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $1.47
Upside: +297.96%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $13.56
Upside: +17.99%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $72.90
Upside: +30.32%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $19.03
Upside: +10.35%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $501.18
Upside: +19.72%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $245.30
Upside: -12.76%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $25.79
Upside: +121.02%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $113.10
Upside: +30.86%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $4.03
Upside: -44.17%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $3.53
Upside: +23,271.10%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $29.22
Upside: -52.09%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $77.84
Upside: +28.47%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $13.95
Upside: -13.98%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $34.96
Upside: +28.72%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $171.49
Upside: +60.36%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.87
Upside: +596.86%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.31
Upside: +565.61%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $6.87
Upside: +773.36%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.79
Upside: +1,798.73%